MX2022002371A - Un anticuerpo de dominio único para dirigirse al antígeno de membrana específico de la próstata (psma). - Google Patents

Un anticuerpo de dominio único para dirigirse al antígeno de membrana específico de la próstata (psma).

Info

Publication number
MX2022002371A
MX2022002371A MX2022002371A MX2022002371A MX2022002371A MX 2022002371 A MX2022002371 A MX 2022002371A MX 2022002371 A MX2022002371 A MX 2022002371A MX 2022002371 A MX2022002371 A MX 2022002371A MX 2022002371 A MX2022002371 A MX 2022002371A
Authority
MX
Mexico
Prior art keywords
psma
specific membrane
prostate specific
membrane antigen
domain antibody
Prior art date
Application number
MX2022002371A
Other languages
English (en)
Inventor
Niv Papo
Lior Rosenfeld
Original Assignee
Nat Institute For Biotechnology In The Negev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Institute For Biotechnology In The Negev Ltd filed Critical Nat Institute For Biotechnology In The Negev Ltd
Publication of MX2022002371A publication Critical patent/MX2022002371A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención, en algunas modalidades de la misma, está dirigida a un polipéptido de unión a antígeno que tiene una mayor afinidad de unión al antígeno de membrana específico de la próstata (PSMA). En algunas modalidades, la presente invención se refiere además al uso del polipéptido de unión a antígeno en el diagnóstico y tratamiento de enfermedades asociadas con expresión elevada de PSMA, tal como el cáncer de próstata.
MX2022002371A 2019-08-29 2020-08-30 Un anticuerpo de dominio único para dirigirse al antígeno de membrana específico de la próstata (psma). MX2022002371A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962893264P 2019-08-29 2019-08-29
PCT/IL2020/050940 WO2021038571A1 (en) 2019-08-29 2020-08-30 A single-domain antibody for targeting prostate specific membrane antigen (psma)

Publications (1)

Publication Number Publication Date
MX2022002371A true MX2022002371A (es) 2022-06-08

Family

ID=74684983

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002371A MX2022002371A (es) 2019-08-29 2020-08-30 Un anticuerpo de dominio único para dirigirse al antígeno de membrana específico de la próstata (psma).

Country Status (11)

Country Link
US (1) US20220306764A1 (es)
EP (1) EP4021941A4 (es)
JP (1) JP2022546422A (es)
KR (1) KR20220106956A (es)
CN (1) CN114787192B (es)
AU (1) AU2020335394A1 (es)
BR (1) BR112022003735A2 (es)
CA (1) CA3149754A1 (es)
IL (1) IL290963A (es)
MX (1) MX2022002371A (es)
WO (1) WO2021038571A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3002674A1 (en) * 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
CN105524170A (zh) * 2016-02-03 2016-04-27 南昌大学 能特异结合前列腺特异性膜抗原的纳米抗体
US20190225671A1 (en) * 2016-08-24 2019-07-25 Teneobio, Inc. Transgenic non-human animals producing modified heavy chain-only antibodies

Also Published As

Publication number Publication date
IL290963A (en) 2022-04-01
BR112022003735A2 (pt) 2022-06-21
KR20220106956A (ko) 2022-08-01
WO2021038571A8 (en) 2022-11-17
CA3149754A1 (en) 2021-03-04
EP4021941A1 (en) 2022-07-06
CN114787192B (zh) 2024-08-09
EP4021941A4 (en) 2023-08-30
AU2020335394A1 (en) 2022-03-24
JP2022546422A (ja) 2022-11-04
CN114787192A (zh) 2022-07-22
US20220306764A1 (en) 2022-09-29
WO2021038571A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
JOP20160154B1 (ar) أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
PH12020551160A1 (en) Chimeric antigen receptors targeting cd70
PH12019500603A1 (en) Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
MX2021000392A (es) Anticuerpos anti-mesotelina.
SA522431672B1 (ar) Cd3 أجسام مضادة للارتباط بـ
MX2018016404A (es) Anticuerpos de union a cd3.
MY195059A (en) Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
MX2021004808A (es) Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos.
MY159837A (en) Therapeutic dll4 binding proteins
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
SA520420109B1 (ar) أجسام مضادة
MX2021000783A (es) Anticuerpos humanizados contra psma.
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
EP4282434A3 (en) Antibodies, uses thereof and conjugates thereof
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
WO2018226985A3 (en) GUIDED COMBINATORY THERAPEUTIC ANTIBODY
MX2024007390A (es) Anticuerpo completamente humanizado y receptor de antigeno quimerico (car) dirigido al subtipo d de la familia c5 del receptor acoplado a proteina g (gprc5d) y usos del mismo.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
MX2021015271A (es) Uso de moleculas biespecificas de union a antigeno que se unen a psma y cd3 en combinacion con la estimulacion conjunta de 4-1bb.
MX2022002371A (es) Un anticuerpo de dominio único para dirigirse al antígeno de membrana específico de la próstata (psma).
MX2024002407A (es) Anticuerpos y conjugados sirp-alfa.
MX2022003762A (es) Molécula de unión específica para el factor inhibidor de la leucemia (lif) y uso de la misma.